Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Pharmacological Bulletin ; (12): 29-35, 2023.
Article Dans Chinois | WPRIM | ID: wpr-1013874

Résumé

Aim To investigate the effects of dagliflozin (DAPA) on atrial tachyarrhythmia (AT) in rats with right heart failure (RHF) due to pulmonary arterial hypertension (PAH) and the underlying mechanisms. Methods Sixty male SD rats were randomly divided into four groups: control group (CTL group), model group (MCT group), MCT + low-dose DAPA intervention group (MCT + LD group) and MCT + high-dose DAPA intervention group (MCT + HD group). After 35 days of continuous intervention, the model and cardiac function evaluation, atrial structural remodelling assessment, inflammatory factor detection, and in vivo cardiac electrophysiology experiments were completed. Results DAPA reduced menn pulmonaryarterial pressure (mPAP) and menn right ventricular pressure (mRVP) in the model rats (P <0.05), attenuated the inflammatory response (P < 0.05), reduced right atrial fibrosis (P <0.05), reduced AT induction rate (P < 0.05) and mean atrial tachyarrhythmia duration (MATD) (P < 0.05), the extent of which was more pronounced in the high-dose DAPA intervention group. Conclusions DAPA can reduce AT susceptibility in PAH-induced RHF rats, and the mechanisms may be related to the inhibition of systemic inflammation and anti-atrial fibrosis by DAPA.

2.
Saudi Medical Journal. 2014; 35 (8): 796-801
Dans Anglais | IMEMR | ID: emr-148864

Résumé

Microribonucleic acids [miRNAs] are small non-coding RNAs, which control diverse cellular functions by either promoting degradation or inhibiting target messenger RNA translation. An aberrant expression profile of miRNAs has been linked to human diseases, including cardiovascular dysfunction. This review summarizes the latest insights in the identification of vascular-specific miRNAs and the underlying mechanisms for their roles in vascular restenosis mainly by influencing the proliferation and migration of vascular smooth muscle cell. Here, we discuss miRNA-based drug and gene therapy in vascular restenosis


Sujets)
Humains , Sténose pathologique , microARN , Resténose coronaire , Thérapie génétique
SÉLECTION CITATIONS
Détails de la recherche